nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—IL3—lymph node—bile duct cancer	0.0207	0.18	CbGeAlD
Amlexanox—S100A13—liver—bile duct cancer	0.0128	0.111	CbGeAlD
Amlexanox—S100A12—liver—bile duct cancer	0.0127	0.11	CbGeAlD
Amlexanox—S100A13—lymph node—bile duct cancer	0.00984	0.0854	CbGeAlD
Amlexanox—S100A12—lymph node—bile duct cancer	0.00971	0.0842	CbGeAlD
Amlexanox—PDE4D—liver—bile duct cancer	0.00845	0.0733	CbGeAlD
Amlexanox—FGF1—liver—bile duct cancer	0.0079	0.0685	CbGeAlD
Amlexanox—PDE4B—pancreas—bile duct cancer	0.007	0.0608	CbGeAlD
Amlexanox—PDE4D—lymph node—bile duct cancer	0.00648	0.0562	CbGeAlD
Amlexanox—FGF1—lymph node—bile duct cancer	0.00606	0.0526	CbGeAlD
Amlexanox—PDE4A—lymph node—bile duct cancer	0.00573	0.0497	CbGeAlD
Amlexanox—PDE4B—liver—bile duct cancer	0.00446	0.0387	CbGeAlD
Amlexanox—PDE4B—lymph node—bile duct cancer	0.00342	0.0296	CbGeAlD
Amlexanox—IL3—Cytokine Signaling in Immune system—IL6—bile duct cancer	0.0017	0.00192	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling events of B Cell Receptor (BCR)—NRAS—bile duct cancer	0.00168	0.0019	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling of activated FGFR—EGFR—bile duct cancer	0.00168	0.0019	CbGpPWpGaD
Amlexanox—FGF1—Regulation of Actin Cytoskeleton—EGFR—bile duct cancer	0.00168	0.0019	CbGpPWpGaD
Amlexanox—FGF1—Signaling by SCF-KIT—KRAS—bile duct cancer	0.00166	0.00188	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB4—EGFR—bile duct cancer	0.00165	0.00187	CbGpPWpGaD
Amlexanox—FGF1—Signaling by Insulin receptor—HRAS—bile duct cancer	0.00165	0.00186	CbGpPWpGaD
Amlexanox—FGF1—DAP12 interactions—NRAS—bile duct cancer	0.00161	0.00182	CbGpPWpGaD
Amlexanox—FGF1—Fc epsilon receptor (FCERI) signaling—NRAS—bile duct cancer	0.00161	0.00182	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR in disease—NRAS—bile duct cancer	0.00161	0.00182	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR—NRAS—bile duct cancer	0.00159	0.0018	CbGpPWpGaD
Amlexanox—FGF1—Regulation of Actin Cytoskeleton—KRAS—bile duct cancer	0.00159	0.00179	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling of activated FGFR—KRAS—bile duct cancer	0.00159	0.00179	CbGpPWpGaD
Amlexanox—FGF1—Downstream signal transduction—EGFR—bile duct cancer	0.00158	0.00179	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR in Cancer—NRAS—bile duct cancer	0.00158	0.00178	CbGpPWpGaD
Amlexanox—FGF1—Signaling by Insulin receptor—IL6—bile duct cancer	0.00158	0.00178	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR—EGFR—bile duct cancer	0.00157	0.00178	CbGpPWpGaD
Amlexanox—FGF1—Signaling by PDGF—NRAS—bile duct cancer	0.00157	0.00178	CbGpPWpGaD
Amlexanox—FGF1—Disease—IDH1—bile duct cancer	0.00157	0.00177	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB2—EGFR—bile duct cancer	0.00156	0.00177	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB4—KRAS—bile duct cancer	0.00156	0.00177	CbGpPWpGaD
Amlexanox—FGF1—DAP12 signaling—EGFR—bile duct cancer	0.00156	0.00176	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—RNF43—bile duct cancer	0.00155	0.00176	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bile duct cancer	0.00153	0.00173	CbGpPWpGaD
Amlexanox—PDE4D—Myometrial Relaxation and Contraction Pathways—IL6—bile duct cancer	0.00152	0.00172	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—NRAS—bile duct cancer	0.00151	0.00171	CbGpPWpGaD
Amlexanox—FGF1—Downstream signal transduction—KRAS—bile duct cancer	0.00149	0.00169	CbGpPWpGaD
Amlexanox—FGF1—B Cell Activation—NRAS—bile duct cancer	0.00149	0.00168	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR—KRAS—bile duct cancer	0.00149	0.00168	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—RNF43—bile duct cancer	0.00148	0.00167	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB2—KRAS—bile duct cancer	0.00148	0.00167	CbGpPWpGaD
Amlexanox—FGF1—DAP12 signaling—KRAS—bile duct cancer	0.00147	0.00166	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—GNAS—bile duct cancer	0.00147	0.00166	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR in disease—EGFR—bile duct cancer	0.00146	0.00166	CbGpPWpGaD
Amlexanox—FGF1—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.00146	0.00166	CbGpPWpGaD
Amlexanox—FGF1—DAP12 interactions—EGFR—bile duct cancer	0.00146	0.00166	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR—EGFR—bile duct cancer	0.00145	0.00164	CbGpPWpGaD
Amlexanox—S100A12—Immune System—HGF—bile duct cancer	0.00145	0.00164	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—bile duct cancer	0.00145	0.00164	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—ERBB2—bile duct cancer	0.00144	0.00163	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.00144	0.00163	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—ERBB2—bile duct cancer	0.00144	0.00162	CbGpPWpGaD
Amlexanox—FGF1—Signaling by PDGF—EGFR—bile duct cancer	0.00143	0.00162	CbGpPWpGaD
Amlexanox—FGF1—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.00142	0.00161	CbGpPWpGaD
Amlexanox—FGF1—Signaling by SCF-KIT—HRAS—bile duct cancer	0.00141	0.00159	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—TGFB1—bile duct cancer	0.00141	0.00159	CbGpPWpGaD
Amlexanox—FGF1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.00141	0.00159	CbGpPWpGaD
Amlexanox—FGF1—DAP12 interactions—KRAS—bile duct cancer	0.00138	0.00156	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR in disease—KRAS—bile duct cancer	0.00138	0.00156	CbGpPWpGaD
Amlexanox—FGF1—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.00138	0.00156	CbGpPWpGaD
Amlexanox—FGF1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.00138	0.00156	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR—KRAS—bile duct cancer	0.00137	0.00155	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—RNF43—bile duct cancer	0.00137	0.00155	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.00136	0.00154	CbGpPWpGaD
Amlexanox—FGF1—B Cell Activation—EGFR—bile duct cancer	0.00136	0.00153	CbGpPWpGaD
Amlexanox—FGF1—Signaling by PDGF—KRAS—bile duct cancer	0.00135	0.00153	CbGpPWpGaD
Amlexanox—FGF1—Signaling by SCF-KIT—IL6—bile duct cancer	0.00135	0.00153	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.00135	0.00153	CbGpPWpGaD
Amlexanox—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—bile duct cancer	0.00134	0.00152	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—GNAS—bile duct cancer	0.00133	0.00151	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB4—HRAS—bile duct cancer	0.00133	0.0015	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—KRAS—bile duct cancer	0.0013	0.00147	CbGpPWpGaD
Amlexanox—FGF1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.0013	0.00147	CbGpPWpGaD
Amlexanox—FGF1—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.0013	0.00147	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.00129	0.00146	CbGpPWpGaD
Amlexanox—FGF1—B Cell Activation—KRAS—bile duct cancer	0.00128	0.00145	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—GNAS—bile duct cancer	0.00128	0.00144	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—RNF43—bile duct cancer	0.00128	0.00144	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TGFBR2—bile duct cancer	0.00127	0.00144	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB4—IL6—bile duct cancer	0.00127	0.00144	CbGpPWpGaD
Amlexanox—FGF1—Downstream signal transduction—HRAS—bile duct cancer	0.00127	0.00143	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR—HRAS—bile duct cancer	0.00126	0.00143	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB2—HRAS—bile duct cancer	0.00126	0.00142	CbGpPWpGaD
Amlexanox—FGF1—DAP12 signaling—HRAS—bile duct cancer	0.00125	0.00141	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.00123	0.00139	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—GNAS—bile duct cancer	0.00123	0.00139	CbGpPWpGaD
Amlexanox—FGF1—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.00123	0.00138	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—GNAS—bile duct cancer	0.00122	0.00137	CbGpPWpGaD
Amlexanox—FGF1—Downstream signal transduction—IL6—bile duct cancer	0.00121	0.00137	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR—IL6—bile duct cancer	0.00121	0.00137	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—SMAD4—bile duct cancer	0.00121	0.00136	CbGpPWpGaD
Amlexanox—FGF1—Signaling by ERBB2—IL6—bile duct cancer	0.0012	0.00136	CbGpPWpGaD
Amlexanox—FGF1—DAP12 signaling—IL6—bile duct cancer	0.0012	0.00135	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR in disease—HRAS—bile duct cancer	0.00118	0.00133	CbGpPWpGaD
Amlexanox—FGF1—DAP12 interactions—HRAS—bile duct cancer	0.00118	0.00133	CbGpPWpGaD
Amlexanox—FGF1—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00118	0.00133	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR—HRAS—bile duct cancer	0.00117	0.00132	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—GNAS—bile duct cancer	0.00116	0.00131	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—TP53—bile duct cancer	0.00116	0.00131	CbGpPWpGaD
Amlexanox—FGF1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.00116	0.00131	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.00116	0.00131	CbGpPWpGaD
Amlexanox—FGF1—Signaling by PDGF—HRAS—bile duct cancer	0.00115	0.0013	CbGpPWpGaD
Amlexanox—FGF1—Signaling by FGFR in disease—IL6—bile duct cancer	0.00113	0.00127	CbGpPWpGaD
Amlexanox—FGF1—DAP12 interactions—IL6—bile duct cancer	0.00113	0.00127	CbGpPWpGaD
Amlexanox—FGF1—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.00113	0.00127	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—GNAS—bile duct cancer	0.00113	0.00127	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR—IL6—bile duct cancer	0.00112	0.00126	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—HRAS—bile duct cancer	0.00111	0.00125	CbGpPWpGaD
Amlexanox—FGF1—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.00111	0.00125	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—GNAS—bile duct cancer	0.0011	0.00125	CbGpPWpGaD
Amlexanox—FGF1—Signaling by PDGF—IL6—bile duct cancer	0.0011	0.00124	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—NRAS—bile duct cancer	0.0011	0.00124	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—NRAS—bile duct cancer	0.00109	0.00124	CbGpPWpGaD
Amlexanox—FGF1—B Cell Activation—HRAS—bile duct cancer	0.00109	0.00123	CbGpPWpGaD
Amlexanox—IL3—Immune System—ERBB2—bile duct cancer	0.00104	0.00118	CbGpPWpGaD
Amlexanox—FGF1—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.00104	0.00118	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—GNAS—bile duct cancer	0.00102	0.00115	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—EGFR—bile duct cancer	0.000998	0.00113	CbGpPWpGaD
Amlexanox—FGF1—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000997	0.00113	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—EGFR—bile duct cancer	0.000996	0.00113	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—KRAS—bile duct cancer	0.000942	0.00107	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—KRAS—bile duct cancer	0.000941	0.00106	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—NRAS—bile duct cancer	0.000869	0.000982	CbGpPWpGaD
Amlexanox—S100A12—Immune System—ERBB2—bile duct cancer	0.000837	0.000946	CbGpPWpGaD
Amlexanox—FGF1—Disease—TGFBR2—bile duct cancer	0.000833	0.000942	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HGF—bile duct cancer	0.000829	0.000937	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—ERBB2—bile duct cancer	0.000821	0.000928	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TGFBR2—bile duct cancer	0.000816	0.000923	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—HRAS—bile duct cancer	0.000801	0.000905	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—HRAS—bile duct cancer	0.000799	0.000904	CbGpPWpGaD
Amlexanox—IL3—Immune System—NRAS—bile duct cancer	0.000794	0.000898	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—EGFR—bile duct cancer	0.000792	0.000895	CbGpPWpGaD
Amlexanox—FGF1—Disease—SMAD4—bile duct cancer	0.000789	0.000891	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—ERBB2—bile duct cancer	0.000788	0.000891	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—GNAS—bile duct cancer	0.000787	0.00089	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SMAD4—bile duct cancer	0.000773	0.000873	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—IL6—bile duct cancer	0.000767	0.000867	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—IL6—bile duct cancer	0.000765	0.000865	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—KRAS—bile duct cancer	0.000748	0.000846	CbGpPWpGaD
Amlexanox—IL3—Immune System—EGFR—bile duct cancer	0.000724	0.000818	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TGFBR2—bile duct cancer	0.000711	0.000803	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—GNAS—bile duct cancer	0.000685	0.000775	CbGpPWpGaD
Amlexanox—IL3—Immune System—KRAS—bile duct cancer	0.000684	0.000773	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TGFBR2—bile duct cancer	0.000676	0.000764	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—ERBB2—bile duct cancer	0.000675	0.000763	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SMAD4—bile duct cancer	0.000673	0.00076	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—GNAS—bile duct cancer	0.000652	0.000737	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SMAD4—bile duct cancer	0.00064	0.000724	CbGpPWpGaD
Amlexanox—S100A12—Immune System—NRAS—bile duct cancer	0.000637	0.000719	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—HRAS—bile duct cancer	0.000636	0.000719	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TGFBR2—bile duct cancer	0.000626	0.000707	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—NRAS—bile duct cancer	0.000625	0.000706	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—IL6—bile duct cancer	0.000609	0.000688	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—GNAS—bile duct cancer	0.000604	0.000682	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—NRAS—bile duct cancer	0.0006	0.000678	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SMAD4—bile duct cancer	0.000592	0.00067	CbGpPWpGaD
Amlexanox—FGF1—Disease—NOS2—bile duct cancer	0.000587	0.000664	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TGFBR2—bile duct cancer	0.000583	0.000659	CbGpPWpGaD
Amlexanox—IL3—Immune System—HRAS—bile duct cancer	0.000581	0.000657	CbGpPWpGaD
Amlexanox—S100A12—Immune System—EGFR—bile duct cancer	0.00058	0.000655	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—MMP9—bile duct cancer	0.000579	0.000654	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—EGFR—bile duct cancer	0.000569	0.000643	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—GNAS—bile duct cancer	0.000563	0.000636	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—NRAS—bile duct cancer	0.000557	0.000629	CbGpPWpGaD
Amlexanox—IL3—Immune System—IL6—bile duct cancer	0.000556	0.000629	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SMAD4—bile duct cancer	0.000552	0.000624	CbGpPWpGaD
Amlexanox—S100A12—Immune System—KRAS—bile duct cancer	0.000548	0.000619	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—EGFR—bile duct cancer	0.000546	0.000618	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—KRAS—bile duct cancer	0.000538	0.000608	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—KRAS—bile duct cancer	0.000516	0.000583	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—NRAS—bile duct cancer	0.000513	0.00058	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—EGFR—bile duct cancer	0.000507	0.000574	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—NRAS—bile duct cancer	0.000485	0.000548	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—KRAS—bile duct cancer	0.000479	0.000542	CbGpPWpGaD
Amlexanox—FGF1—Immune System—ERBB2—bile duct cancer	0.000478	0.00054	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TGFB1—bile duct cancer	0.000477	0.000539	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—EGFR—bile duct cancer	0.000468	0.000529	CbGpPWpGaD
Amlexanox—S100A12—Immune System—HRAS—bile duct cancer	0.000466	0.000526	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—NRAS—bile duct cancer	0.000461	0.000522	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—HRAS—bile duct cancer	0.000457	0.000516	CbGpPWpGaD
Amlexanox—S100A12—Immune System—IL6—bile duct cancer	0.000446	0.000504	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—KRAS—bile duct cancer	0.000442	0.0005	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—EGFR—bile duct cancer	0.000442	0.000499	CbGpPWpGaD
Amlexanox—FGF1—Disease—ERBB2—bile duct cancer	0.000441	0.000499	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—HRAS—bile duct cancer	0.000439	0.000496	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—IL6—bile duct cancer	0.000437	0.000494	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—ERBB2—bile duct cancer	0.000432	0.000489	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTGS2—bile duct cancer	0.000432	0.000488	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—NRAS—bile duct cancer	0.000427	0.000483	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—EGFR—bile duct cancer	0.00042	0.000475	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—KRAS—bile duct cancer	0.000417	0.000472	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—HRAS—bile duct cancer	0.000407	0.000461	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—KRAS—bile duct cancer	0.000397	0.000449	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TP53—bile duct cancer	0.000393	0.000444	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—IL6—bile duct cancer	0.00039	0.000441	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—EGFR—bile duct cancer	0.000389	0.00044	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ERBB2—bile duct cancer	0.000376	0.000425	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—HRAS—bile duct cancer	0.000376	0.000425	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MMP9—bile duct cancer	0.000371	0.000419	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—KRAS—bile duct cancer	0.000367	0.000415	CbGpPWpGaD
Amlexanox—FGF1—Immune System—NRAS—bile duct cancer	0.000364	0.000411	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—IL6—bile duct cancer	0.00036	0.000406	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ERBB2—bile duct cancer	0.000358	0.000405	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—HRAS—bile duct cancer	0.000355	0.000401	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—IL6—bile duct cancer	0.000339	0.000384	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—HRAS—bile duct cancer	0.000338	0.000382	CbGpPWpGaD
Amlexanox—FGF1—Disease—NRAS—bile duct cancer	0.000336	0.00038	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ERBB2—bile duct cancer	0.000332	0.000375	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EGFR—bile duct cancer	0.000331	0.000375	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—NRAS—bile duct cancer	0.000329	0.000372	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—IL6—bile duct cancer	0.000323	0.000365	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MMP9—bile duct cancer	0.000323	0.000365	CbGpPWpGaD
Amlexanox—FGF1—Immune System—KRAS—bile duct cancer	0.000313	0.000354	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—HRAS—bile duct cancer	0.000312	0.000353	CbGpPWpGaD
Amlexanox—FGF1—Disease—TGFB1—bile duct cancer	0.000312	0.000353	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ERBB2—bile duct cancer	0.000309	0.000349	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MMP9—bile duct cancer	0.000307	0.000347	CbGpPWpGaD
Amlexanox—FGF1—Disease—EGFR—bile duct cancer	0.000306	0.000346	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TGFB1—bile duct cancer	0.000306	0.000346	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EGFR—bile duct cancer	0.0003	0.000339	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—IL6—bile duct cancer	0.000299	0.000338	CbGpPWpGaD
Amlexanox—FGF1—Disease—KRAS—bile duct cancer	0.000289	0.000327	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—NRAS—bile duct cancer	0.000286	0.000324	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MMP9—bile duct cancer	0.000284	0.000321	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—KRAS—bile duct cancer	0.000283	0.00032	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—NRAS—bile duct cancer	0.000273	0.000308	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TGFB1—bile duct cancer	0.000266	0.000301	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HRAS—bile duct cancer	0.000266	0.000301	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MMP9—bile duct cancer	0.000265	0.0003	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EGFR—bile duct cancer	0.000261	0.000295	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL6—bile duct cancer	0.000255	0.000288	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TGFB1—bile duct cancer	0.000253	0.000286	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NRAS—bile duct cancer	0.000252	0.000285	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TP53—bile duct cancer	0.000252	0.000284	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EGFR—bile duct cancer	0.000248	0.000281	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—KRAS—bile duct cancer	0.000246	0.000279	CbGpPWpGaD
Amlexanox—FGF1—Disease—HRAS—bile duct cancer	0.000246	0.000278	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HRAS—bile duct cancer	0.000241	0.000272	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NRAS—bile duct cancer	0.000235	0.000266	CbGpPWpGaD
Amlexanox—FGF1—Disease—IL6—bile duct cancer	0.000235	0.000266	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—KRAS—bile duct cancer	0.000235	0.000265	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TGFB1—bile duct cancer	0.000234	0.000265	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL6—bile duct cancer	0.00023	0.00026	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EGFR—bile duct cancer	0.00023	0.00026	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TP53—bile duct cancer	0.000219	0.000248	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TGFB1—bile duct cancer	0.000219	0.000247	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KRAS—bile duct cancer	0.000217	0.000245	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EGFR—bile duct cancer	0.000214	0.000242	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HRAS—bile duct cancer	0.00021	0.000237	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TP53—bile duct cancer	0.000209	0.000236	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KRAS—bile duct cancer	0.000202	0.000229	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL6—bile duct cancer	0.000201	0.000227	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HRAS—bile duct cancer	0.000199	0.000225	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TP53—bile duct cancer	0.000193	0.000218	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL6—bile duct cancer	0.000191	0.000216	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HRAS—bile duct cancer	0.000185	0.000209	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TP53—bile duct cancer	0.00018	0.000203	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL6—bile duct cancer	0.000177	0.0002	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HRAS—bile duct cancer	0.000172	0.000194	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL6—bile duct cancer	0.000165	0.000186	CbGpPWpGaD
